Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Net Margin (2016 - 2025)

Enanta Pharmaceuticals' Net Margin history spans 14 years, with the latest figure at 64.13% for Q4 2025.

  • For Q4 2025, Net Margin rose 6730.0% year-over-year to 64.13%; the TTM value through Dec 2025 reached 106.8%, up 5367.0%, while the annual FY2025 figure was 125.36%, 4908.0% up from the prior year.
  • Net Margin reached 64.13% in Q4 2025 per ENTA's latest filing, up from 123.64% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 64.13% in Q4 2025 to a low of 347.41% in Q3 2021.
  • Average Net Margin over 5 years is 159.23%, with a median of 150.09% recorded in 2023.
  • Peak YoY movement for Net Margin: plummeted -22325bps in 2021, then surged 21781bps in 2022.
  • A 5-year view of Net Margin shows it stood at 108.92% in 2021, then dropped by -13bps to 122.9% in 2022, then tumbled by -51bps to 185.56% in 2023, then grew by 29bps to 131.43% in 2024, then soared by 51bps to 64.13% in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Net Margin are 64.13% (Q4 2025), 123.64% (Q3 2025), and 99.68% (Q2 2025).